3 798

Cited 21 times in

Adjuvant hepatic arterial infusional chemotherapy with 5-fluorouracil and cisplatin after curative resection of hepatocellular carcinoma

DC Field Value Language
dc.contributor.author김경식-
dc.contributor.author김도영-
dc.contributor.author김승업-
dc.contributor.author박미숙-
dc.contributor.author박준용-
dc.contributor.author안상훈-
dc.contributor.author이광훈-
dc.contributor.author이도연-
dc.contributor.author한광협-
dc.date.accessioned2014-12-20T17:22:30Z-
dc.date.available2014-12-20T17:22:30Z-
dc.date.issued2011-
dc.identifier.issn0030-2414-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/94482-
dc.description.abstractOBJECTIVES: We investigated whether adjuvant hepatic arterial infusional chemotherapy (HAIC) with 5-fluorouracil (5-FU) and cisplatin reduces the recurrence of hepatocellular carcinoma (HCC) after curative resection. METHODS: Between January 2006 and December 2008, 31 HCC patients received four cycles of adjuvant HAIC with 5-FU and cisplatin via port system after curative resection. During the same period, 62 patients, who did not take any adjuvant therapy, were selected as controls. RESULTS: Tumor characteristics, such as distribution of TNM stage, pathologic differentiation, portal vein invasion, or microscopic invasion did not differ between control and adjuvant groups. During follow-up, recurrence developed in 11 adjuvant (35.5%) and 24 control patients (38.7%; p = 0.823). Tumor progression after recurrence was the cause of death in 2 adjuvant (28.6%) and 7 control patients (38.8%; p = 0.912). The 2-year recurrence rate was 9.1% in the adjuvant group and 4.2% in the control group, with the median recurrence-free survival time being 10.5 and 7.5 months, respectively (p = 0.324). The 3-year cumulative survival rate was 73.3% in the adjuvant group and 68.3% in the control group (p = 0.355). CONCLUSION: Adjuvant HAIC with 5-FU and cisplatin did not offer any beneficial effect on the recurrence after curative resection of HCC-
dc.description.statementOfResponsibilityopen-
dc.format.extent184~191-
dc.relation.isPartOfONCOLOGY-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAdult-
dc.subject.MESHAntineoplastic Combined Chemotherapy Protocols/therapeutic use*-
dc.subject.MESHCarcinoma, Hepatocellular/drug therapy*-
dc.subject.MESHCarcinoma, Hepatocellular/pathology-
dc.subject.MESHCarcinoma, Hepatocellular/surgery*-
dc.subject.MESHChemotherapy, Adjuvant-
dc.subject.MESHCisplatin/administration & dosage-
dc.subject.MESHDisease Progression-
dc.subject.MESHDisease-Free Survival-
dc.subject.MESHFemale-
dc.subject.MESHFluorouracil/administration & dosage-
dc.subject.MESHFollow-Up Studies-
dc.subject.MESHHumans-
dc.subject.MESHInfusions, Intra-Arterial-
dc.subject.MESHLiver Neoplasms/drug therapy*-
dc.subject.MESHLiver Neoplasms/pathology-
dc.subject.MESHLiver Neoplasms/surgery*-
dc.subject.MESHMale-
dc.subject.MESHMiddle Aged-
dc.subject.MESHNeoplasm Recurrence, Local/prevention & control-
dc.subject.MESHProspective Studies-
dc.subject.MESHSurvival Rate-
dc.subject.MESHTreatment Outcome-
dc.subject.MESHYoung Adult-
dc.titleAdjuvant hepatic arterial infusional chemotherapy with 5-fluorouracil and cisplatin after curative resection of hepatocellular carcinoma-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학)-
dc.contributor.googleauthorKim D.Y.-
dc.contributor.googleauthorAhn S.H.-
dc.contributor.googleauthorKim S.U.-
dc.contributor.googleauthorChoi S.B.-
dc.contributor.googleauthorLee K.-H.-
dc.contributor.googleauthorPark M.S.-
dc.contributor.googleauthorPark J.Y.-
dc.contributor.googleauthorLee D.Y.-
dc.contributor.googleauthorHan K.-H.-
dc.contributor.googleauthorKim K.S-
dc.identifier.doi10.1159/000333827-
dc.admin.authorfalse-
dc.admin.mappingfalse-
dc.contributor.localIdA00299-
dc.contributor.localIdA00654-
dc.contributor.localIdA01463-
dc.contributor.localIdA01675-
dc.contributor.localIdA02226-
dc.contributor.localIdA02676-
dc.contributor.localIdA02718-
dc.contributor.localIdA04268-
dc.contributor.localIdA00385-
dc.relation.journalcodeJ02416-
dc.identifier.eissn1423-0232-
dc.identifier.pmid22067673-
dc.identifier.urlhttp://www.karger.com/Article/FullText/333827-
dc.subject.keywordHepatocellular carcinoma-
dc.subject.keywordAdjuvant therapy-
dc.subject.keywordHepatic-
dc.subject.keywordarterial infusional chemotherapy-
dc.contributor.alternativeNameKim, Kyung Sik-
dc.contributor.alternativeNameKim, Do Young-
dc.contributor.alternativeNameKim, Seung Up-
dc.contributor.alternativeNamePark, Mi Sook-
dc.contributor.alternativeNamePark, Jun Yong-
dc.contributor.alternativeNameAhn, Sang Hoon-
dc.contributor.alternativeNameLee, Kwang Hun-
dc.contributor.alternativeNameLee, Do Yun-
dc.contributor.alternativeNameHan, Kwang Hyup-
dc.contributor.affiliatedAuthorKim, Kyung Sik-
dc.contributor.affiliatedAuthorKim, Seung Up-
dc.contributor.affiliatedAuthorPark, Mi-Suk-
dc.contributor.affiliatedAuthorPark, Jun Yong-
dc.contributor.affiliatedAuthorAhn, Sang Hoon-
dc.contributor.affiliatedAuthorLee, Kwang Hun-
dc.contributor.affiliatedAuthorLee, Do Yun-
dc.contributor.affiliatedAuthorHan, Kwang Hyup-
dc.contributor.affiliatedAuthorKim, Do Young-
dc.rights.accessRightsnot free-
dc.citation.volume81-
dc.citation.number3-4-
dc.citation.startPage184-
dc.citation.endPage191-
dc.identifier.bibliographicCitationONCOLOGY, Vol.81(3-4) : 184-191, 2011-
dc.identifier.rimsid27359-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Radiology (영상의학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Surgery (외과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.